Program
LY4214835
A development code.
Its studies are mostly in Neoplasms, led by Eli Lilly.
Furthest: phase 1, since Nov 21, 20251 company-led study, 1 open or runningNext primary completion: Dec 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 11 open or running | phase 1since Nov 21, 2025 | Nov 21, 2025 | Dec 2027phase 1 · NCT07258836 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 21, 2025First study: phase 1 study in NeoplasmsFirst studyNCT07258836 · 41 planned · United States
- Nov 6, 2026Primary completion moved from 2027-01 to 2027-12Date moved laterphase 1 · +11 months · NCT07258836
Ahead
- Dec 2027Primary completion: phase 1 study in NeoplasmsNCT07258836
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07258836Neoplasms · United States | 1 | Recruiting | Dec 2027 | 41 |
How it is read
Names in the registry
- “LY4214835”, 1 entry
Codes read as this program: LY4214835.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.